KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2025)

CRISPR Therapeutics AG's Net Margin history spans 11 years, with the latest figure at 15011.46% for Q4 2025.

  • For Q4 2025, Net Margin fell 1603725.0% year-over-year to 15011.46%; the TTM value through Dec 2025 reached 16543.7%, down 1664326.0%, while the annual FY2025 figure was 16543.7%, 1664329.0% down from the prior year.
  • Net Margin for Q4 2025 was 15011.46% at CRISPR Therapeutics AG, down from 11973.12% in the prior quarter.
  • Across five years, Net Margin topped out at 1025.79% in Q4 2024 and bottomed at 1880950.0% in Q4 2022.
  • The 5-year median for Net Margin is 15431.19% (2021), against an average of 124614.4%.
  • The largest annual shift saw Net Margin crashed -187986834bps in 2022 before it surged 188108419bps in 2023.
  • A 5-year view of Net Margin shows it stood at 1081.66% in 2021, then crashed by -173795bps to 1880950.0% in 2022, then soared by 100bps to 134.19% in 2023, then soared by 664bps to 1025.79% in 2024, then plummeted by -1563bps to 15011.46% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Net Margin are 15011.46% (Q4 2025), 11973.12% (Q3 2025), and 23380.83% (Q2 2025).